Tolerability and Efficacy of Multiple Escalating Doses of Ranibizumab (Lucentis) for Neovascular Age-Related Macular Degeneration
- 30 April 2006
- journal article
- research article
- Published by Elsevier BV in Ophthalmology
- Vol. 113 (4), 623-632.e1
- https://doi.org/10.1016/j.ophtha.2006.01.027
Abstract
No abstract availableKeywords
Funding Information
- Genentech
This publication has 18 references indexed in Scilit:
- Ranibizumab for Treatment of Neovascular Age-Related Macular Degeneration: A Phase I/II Multicenter, Controlled, Multidose StudyOphthalmology, 2006
- Maximum Tolerated Dose of a Humanized Anti–Vascular Endothelial Growth Factor Antibody Fragment for Treating Neovascular Age-Related Macular DegenerationOphthalmology, 2005
- Bevacizumab in Combination With Fluorouracil and Leucovorin: An Active Regimen for First-Line Metastatic Colorectal CancerJournal of Clinical Oncology, 2005
- Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal CancerThe New England Journal of Medicine, 2004
- The epidemiology of age-related macular degenerationAmerican Journal of Ophthalmology, 2004
- VEGF‐TRAPR1R2 suppresses choroidal neovascularization and VEGF‐induced breakdown of the blood–retinal barrierJournal of Cellular Physiology, 2003
- Intrachoroidal Neovascularization in Transgenic Mice Overexpressing Vascular Endothelial Growth Factor in the Retinal Pigment EpitheliumThe American Journal of Pathology, 2001
- Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured fab in complex with antigenJournal of Molecular Biology, 1999
- Comparisons of the Intraocular Tissue Distribution, Pharmacokinetics, and Safety of 125I-Labeled Full-Length and Fab Antibodies in Rhesus Monkeys Following Intravitreal AdministrationToxicologic Pathology, 1999
- Increased expression of angiogenic growth factors in age-related maculopathyBritish Journal of Ophthalmology, 1997